Scientists at George Mason University are working to develop an easy-to-administer COVID-19 antibody test, which could mean using a simple swab in the mouth for saliva.
Dr. Lance Liotta works for the Applied Proteomics and Molecular Medicine Center at GMU. He said they’ve been working on saliva testing for many years and already had a collection device that would work.
“We thought let’s apply our expertise on that topic to that new challenge,” Liotta said.
Image: https://www.nbcwashington.com
The Association of University Research Parks (AURP), a global nonprofit membership organization serving the university and institutional research parks community, today announced its BIO Health Caucus will take place June 3-4, 2020 in a digital environment. AURP’s BIO Health Caucus represents anchor life science institutions building communities of health innovations in the U.S and around the world.
AURP’s 2020 BIO Health Caucus explores trends in life science research, opportunity zone funding, the marriage of life science and philanthropy, and finding funding for projects and facilities during a global pandemic. At this digital event, attendees will discover the role that biomedical clusters play in innovation ecosystems and translating discoveries from lab to market.
Image: Joel Marcus
The Association of University Research Parks (AURP), a global nonprofit membership organization serving the university and institutional research parks community, today announced its BIO Health Caucus will take place June 3-4, 2020 in a digital environment. AURP’s BIO Health Caucus represents anchor life science institutions building communities of health innovations in the U.S and around the world.
AURP’s 2020 BIO Health Caucus explores trends in life science research, opportunity zone funding, the marriage of life science and philanthropy, and finding funding for projects and facilities during a global pandemic. At this digital event, attendees will discover the role that biomedical clusters play in innovation ecosystems and translating discoveries from lab to market.
Image: Joel Marcus
Larry Hogan has got another of his ideas, and this one cracks him up. “I’m gonna call Pence!” says Hogan, startling his chief of staff, Matthew Clark, who sits across a large, round faux-wood table. Hogan, the Republican governor of Maryland, is meeting with his coronavirus command team, a skeleton crew of state officials still reporting to the capitol in Annapolis. The conference rooms are all too narrow, so they are gathered in a cavernous event room, seated in alternate chairs to maintain social distancing. Hogan, a ruddy 63-year-old with jug-handle ears, has in front of him a dispenser of hand sanitizer, a can of Diet Coke and a starfish-shaped conference-call speaker.
Image: https://governor.maryland.gov/governor-larry-hogan/
Sponsored by the Division of Strategic Partnerships and Applied Research, the StarTUp Accelerator supports student and local business ventures in an intensive eight-week, cohort-based fellowship where start-up businesses take residency and work in a collaborative space to accelerate their ventures. The inaugural cohort is a diverse group that includes two student-based ventures, a 100% halal-certified consumer cosmetics brand, a sports betting game from recent TU grads, and ventures from current TU faculty.
Sykesville, MD; March 13, 2020- Noble Life Sciences is excited to announce renewal of full accreditation from Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. Noble Life Sciences has held full AAALAC accreditation since October 10, 1989. Accredited contract research organizations (CROs) are re-evaluated every three years through an extensive internal review and on-site inspection conducted by members of AAALAC accreditation council and reviewed by the full council to determine accreditation status.
AstraZeneca will oversee global development, manufacturing, and distribution of the COVID-19 vaccine candidate that was created by researchers at University of Oxford, and is now being studied in a human clinical trial launched last week, the partners said today.
AstraZeneca, the University, and its spinout company Vaccitech—which has joint rights to the platform technology behind the vaccine candidate, ChAdOx1 nCoV-19—said they will start work immediately while hammering out final terms of their collaboration agreement. The partnership is designed to enable rapid production and distribution of the vaccine should it prove effective in clinical studies.
Image: AstraZeneca will oversee global development, manufacturing, and distribution of the COVID-19 vaccine candidate that was created by researchers at University of Oxford, and is now being studied in a human clinical trial launched last week. (University of Oxford)
Vaccitech Ltd and the University of Oxford today announce an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.
The partnership is to begin immediately with the final terms being agreed in the coming weeks. This will allow for rapid vaccination around the world if the COVID-19 vaccine candidate proves to be effective. The vaccine candidate was developed by the University’s Jenner Institute who began trials in humans last week jointly with the University’s Oxford Vaccine Group.
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in a randomized, doubleblind Phase II clinical trial, evaluating the safety and efficacy of its anti-C5aR antibody, avdoralimab (IPH5401), in COVID-19 patients with severe pneumonia.
The primary objective of this investigator-sponsored trial, named FORCEa , is to improve the proportion of COVID-19 patients with severe pneumonia who no longer need to be hospitalized, and to reduce the need for and duration of mechanical ventilation in patients with COVID-19 pneumonia complicated by acute respiratory distress syndrome (ARDS).
Since the enactment of the CARES Act, the Small Business Administration and U.S. Department of the Treasury have continually updated the rules governing the Paycheck Protection Program (PPP) through formal rulemaking and less formal guidance. In some cases, these rules and guidance have contradicted the plain language of the Act itself.
The PPP, of course, is designed to provide businesses and nonprofits with 500 or fewer employees (subject to certain notable exceptions) access to 2 months of payroll for their employees in light of the economic uncertainty brought on by the COVID-19 Pandemic.
